SOD1 and Parkinson disease: These previously cited examples of positive results, along with the ability of Cu2+ATSM to accumulate in damaged tissues in PD, the abovementioned alleged role of SOD1 in the pathogenesis of PD, and the fact that Cu2+ATSM is able to stimulate SOD1 activity support the clinical trial I phase based on the application of Cu2+-ATSM, which is currently underway (NCT03204929) [3].